The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal ant...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Tejani, Mohamedtaki A, Cohen, Roger B, Mehra, Ranee
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2010
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2921255/
https://ncbi.nlm.nih.gov/pubmed/20714355
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak